What This Bill Does · Plain English
GovGreed Synthesis · AI extraction
This bill amends the Social Security Act to extend the period during which certain drugs are exempt from Medicare price negotiation. Specifically, it changes the definition of a 'qualifying single source drug' to grant an 11-year exemption (instead of the standard 7 years) for 'advanced drug products' that use genetically targeted technologies to modulate gene function.
Frequently Asked Questions
Did S.476 pass?
S.476 did not pass and is no longer active. Final stage: COMMITTEE.
What does S.476 do?
This bill amends the Social Security Act to extend the period during which certain drugs are exempt from Medicare price negotiation. Specifically, it changes the definition of a 'qualifying single source drug' to grant an 11-year exemption (instead of the standard 7 years) for 'advanced drug products' that use genetically targeted technologies to modulate gene function.
Full Bill Text
118 S476 IS: Maintaining Investments in New Innovation Act U.S. Senate 2023-02-16 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. II 118th CONGRESS 1st Session S. 476 IN THE SENATE OF THE UNITED STATES February 16, 2023 Mr. Menendez (for himself and Mrs. Blackburn ) introduced the following bill; which was read twice and referred to the Committee on Finance A BILL To amend title XI of the Social Security Act to protect access to genetically targeted technologies. 1. Short title This Act may be cited as the Maintaining Investments in New Innovation Act . 2. Amendment to definition of qualifying single source drug Section 1192(e) of the Social Security Act ( 42 U.S.C. 1320f–1(e) ) is amended— (1) in paragraph (1)(A)(ii), by inserting (or, in the case of an advanced drug product (as defined in paragraph (4)), 11 years) after 7 years ; and (2) by adding at the end the following new paragraph: (4) Advanced drug product defined For purposes of paragraph (1)(A)(ii), the term advanced drug product means a drug that incorporates or utilizes a genetically targeted technology (as defined in section 529A(c)(2) of the Federal Food, Drug, and Cosmetic Act) that may result in the modulation (including suppression, up-regulation, or activation) of the function of a gene or its associated gene product. .
Loading intelligence layer…